HOME >> BIOLOGY >> NEWS
Trial found no impact of Malarone(TM) on performance and alertness tasks

light. There were no significant differences between the test results following MalaroneTM or placebo dosing. These results support those from a previous study where, under normal pressure conditions, MalaroneTM had no impact on traditional psychomotor testing, simulating flying performance nor on the subjective assessment of mood, sleepiness, or fatigue (4).

Adverse events were comparable for both study treatment arms, and all were classified as mild, short lasting and most frequently related to GI problems.

Dr Dereck Tait, Director, Clinical Development said: "These new data provide further evidence for the favourable safety profile of MalaroneTM. The safety and tolerability of MalaroneTM have been demonstrated in several clinical trials, and in two of these, conducted in nearly 2000 non-immune subjects, MalaroneTM had fewer drug related adverse events than mefloquine (5) and chloroquine/proguanil (6)."

MalaroneTM should be started 12 days before travel and continued daily until 7 days after travel, making it ideal for people who spend only a short period of time in an endemic area, such as aircrew.

MalaroneTM is approved for the prophylaxis and treatment of P. falciparum malaria, the most common and serious type of malaria.


'"/>

Contact: Heather Bell
heather_bell@uk.bm.com
44-207-300-6319
Burson-Marsteller
6-May-2004


Page: 1 2

Related biology news :

1. Trial shows which brain cancer patients benefit from temozolomide
2. Trial drugs for Huntingtons disease inconclusive in slowing disease
3. National Institute on Drug Abuse launches National Drug Addiction Treatment Clinical Trials Network
4. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
5. Gene Therapy Trial Approved For Rare Anemia
6. Severe Pain Following Shingles Safely Relieved In Clinical Trial Of Anti-Convulsant Drug Gabapentin
7. Cardiac Clinical Trial Studies Use of Antibiotic In Preventing Heart Attack
8. Clinical Trials Show That Bone Marrow Transplant And Vitamin A Derivative Both Improve Survival From Neuroblastoma
9. Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At UCSF/Mount Zion Cancer Center
10. Targeted Genetics, M.D. Anderson Cancer Center And University Of Pittsburgh Report Phase I Clinical Trial Results Of Gene Therapy Treatment For Cancer
11. Experimental Trial Combines DNA Vaccine With Triple-Drug Therapy To Stop HIV

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2020)... ... 27, 2020 , ... CrucialTrak, a global designer and manufacturer of biometric access ... (CEG) to market and sell its complete line of biometric readers and access ... infrastructure optimization solutions . , Brett Mason, CrucialTrak’s Director of Channel Sales for ...
(Date:5/28/2020)... ... May 28, 2020 , ... Actuate Therapeutics, ... their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at ... place virtually on May 29th, 2020. Dr. Benedito Carneiro, Brown University’s principal investigator ...
(Date:5/21/2020)... ... May 21, 2020 , ... ... background and medical screening, announces the launch of a testing service aimed ... safe. The new service is provided by ClearStar’s Medical Information Services (“MIS”) ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... 23, 2020 , ... Kerafast Inc. , developers of ... the availability of the Delta-G-VSV Pseudotyping System for coronavirus research applications. The system, ... SARS-CoV-2 viral entry and COVID-19 vaccine effectiveness at just biosafety level 2 (BSL-2) ...
(Date:6/23/2020)... ... June 22, 2020 , ... Dracen Pharmaceuticals Inc., announced today ... 22-24 during the American Association for Cancer Research Virtual meeting. One poster describes ... consistent single agent activity in KEAP1 mutant tumor models of NSCLC. ...
(Date:6/11/2020)... ... , ... Greffex, a leading genetic engineering company, with the ... vectors, recently announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce ... successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including ...
(Date:6/11/2020)... ... 2020 , ... Reducing carbon emissions has been and will continue to be ... market dips, ways to reduce CO2 is something we can’t avoid. , To ... biofuels being produced today are created from recycled cooking oil or crops. Unfortunately, these ...
Breaking Biology Technology:
Cached News: